. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: J Arthroplasty. 2020 Mar 4;35(6 Suppl):S201–S206. doi: 10.1016/j.arth.2020.02.047

Table 2.

Primary and secondary outcomes.

	TXA (n=4,423)	No TXA (n=18,998)	Unadjusted Odds Ratio (95% CI)	p-value	Adjusted Odds Ratio (95% CI)	p-value
PJI 2 yrs from surgery	29 (0.7)	239 (1.3)	0.51 (0.20–0.84)	0.014	0.55 (0.42–0.94)	0.033
I&D 2 yrs from surgery	15 (0.3)	116 (0.6)	0.97 (0.51–1.86)	0.93	1.20 (0.62–2.32)	0.59
Revision rate at 2 yrs	46 (1.0)	432 (2.3)	0.59 (0.42–0.83)	0.0027	0.66 (0.46–0.93)	0.019
Transfusion at 1 week	63 (1.4)	2,195 (11.6)	0.15 (0.11–0.19)	<0.0001	0.15 (0.11–0.19)	<0.0001
LOS, median (IQR)	3.0 (0.6)	3.2 (1.2)	0.91^* (0.89–0.93)	<0.0001	0.93^* (0.91–0.95)	<0.0001

Note: This value is not an odds ratio, but a rate ratio. Abbreviations: TXA, tranexamic acid; CI, confidence interval; PJI, periprosthetic joint infection; I&D, irrigation and debridement; yrs, years; LOS, length of stay; IQR, interquartile range. Statistically significant values are highlighted.